Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was upgraded to Buy from Neutral by UBS, with the firm adjusting the price target ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Biogen for a ...
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
7don MSN
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
April 20 (Reuters) - Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater ...
'Mad Money' host Jim Cramer weighs in on stocks including: AES, InterDigital, Infleqtion, Netskope, and Biogen.
Biogen (BIIB) stock is in focus as the company inks a deal worth up to $850M with TJ Bio to buy Greater China rights to ...
With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...
Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst ...
Following its move to secure ex-China rights to the CD38-directed antibody felzartamab, Biogen is doubling down and building ...
Shares of Biogen Inc. BIIB slipped 1.15% to $187.88 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.41% to 7,108.40 and ...
Biogen has agreed to pay up to $850 million to acquire TJ Bio's exclusive rights to felzartamab in the Greater China region, giving it worldwide rights to the investigational drug that is currently in ...
Biogen and Minor League Baseball’s Durham Bulls are joining forces to celebrate “America 250” in the Triangle Community. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results